{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T04:52:12Z","timestamp":1777179132669,"version":"3.51.4"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To determine the impact of the COVID-19 pandemic on antimicrobial consumption and trends of therapeutic drugs for COVID-19 treatments, including corticosteroids, remdesivir and monoclonal antibodies (tocilizumab) from April 2017 to September 2022 in a secondary care NHS Trust in England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective intervention time series analysis was conducted for April 2017 to September 2022 at the Mid Yorkshire Teaching NHS Trust. Data were retrieved from the pharmacy dispensing system as defined daily doses (DDDs) monthly and reported per 1000 occupied bed days (OBDs). Antimicrobial consumption and COVID-19 treatment options were measured. DDDs were calculated according to the classification of antimicrobials for systemic use (J01) and for other drugs classification. Trends for antimicrobial consumption and other therapeutic drugs for treating COVID-19 were also determined in each wave in England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the pandemic: total antibiotic consumption decreased from 826.4 to 728.2 DDDs per 1000 OBDs (P\u200a=\u200a0.0067); piperacillin\/tazobactam use increased (P\u200a&amp;lt;\u200a0.0001) and ciprofloxacin use decreased (P\u200a&amp;lt;\u200a0.0001); there were no changes in Access, Watch, Reserve antibiotic use, and the proportion of antifungal consumption was consistent throughout the study. The use of total antibiotics (P\u200a=\u200a0.024), levofloxacin (P\u200a=\u200a0.0007), piperacillin\/tazobactam (P\u200a=\u200a0.0015) and co-amoxiclav (P\u200a=\u200a0.0198) increased during wave one. Consumption of COVID-19 treatment drugs was highest during wave two, with 624.3 DDDs per 1000 OBDs for dexamethasone (P\u200a=\u200a0.4441), 6.8 DDDs per 1000 OBDs for remdesivir (P\u200a&amp;lt;\u200a0.0001) and 35.01 DDDs per 1000 OBDs for tocilizumab (P\u200a=\u200a0.2544).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>This study determined the consumption of antimicrobials trends before and during the pandemic. The individual wave antimicrobial consumption indicates maximum consumption in the first wave, advocating for antimicrobial stewardship and preparedness for future pandemics.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlae013","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T15:09:40Z","timestamp":1707318580000},"source":"Crossref","is-referenced-by-count":6,"title":["Antimicrobial consumption in an acute NHS Trust during the COVID-19 pandemic: intervention time series analysis"],"prefix":"10.1093","volume":"6","author":[{"given":"Sidra","family":"Khan","sequence":"first","affiliation":[{"name":"Department of Pharmacy, School of Applied Sciences, University of Huddersfield , Huddersfield, HD1 3DH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9640-2474","authenticated-orcid":false,"given":"Stuart E","family":"Bond","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Applied Sciences, University of Huddersfield , Huddersfield, HD1 3DH , UK"},{"name":"Pharmacy Department, Mid Yorkshire Teaching NHS Trust , Wakefield, WF1 4DG , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Lee-Milner","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Mid Yorkshire Teaching NHS Trust , Wakefield, WF1 4DG , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara R","family":"Conway","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Applied Sciences, University of Huddersfield , Huddersfield, HD1 3DH , UK"},{"name":"Institute of Skin Integrity and Infection Prevention, University of Huddersfield , Huddersfield, HD1 3DH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Lattyak","sequence":"additional","affiliation":[{"name":"Statistical Consulting Department, Scientific Computing Associates Corp. , River Forest, IL 60305 , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-7612","authenticated-orcid":false,"given":"Mamoon A","family":"Aldeyab","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, School of Applied Sciences, University of Huddersfield , Huddersfield, HD1 3DH , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"2024022909295953200_dlae013-B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/2042098614554919","article-title":"Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem","volume":"5","author":"Llor","year":"2014","journal-title":"Ther Adv Drug Saf"},{"key":"2024022909295953200_dlae013-B2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"2024022909295953200_dlae013-B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2024022909295953200_dlae013-B4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1017\/ice.2020.368","article-title":"Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York city pandemic surge","volume":"42","author":"Nori","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024022909295953200_dlae013-B5","doi-asserted-by":"crossref","first-page":"e652","DOI":"10.1093\/cid\/ciaa1896","article-title":"Trends in US outpatient antibiotic prescriptions during the COVID-19 pandemic","volume":"73","author":"King","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024022909295953200_dlae013-B6","doi-asserted-by":"crossref","first-page":"e1003682","DOI":"10.1371\/journal.pmed.1003682","article-title":"Sales of antibiotics and hydroxychloroquine in India during the COVID-19 epidemic: an interrupted time series analysis","volume":"18","author":"Sulis","year":"2021","journal-title":"PLoS Med"},{"key":"2024022909295953200_dlae013-B7","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.3399\/BJGP.2020.1051","article-title":"Antimicrobial stewardship in the UK during the COVID-19 pandemic: a population-based cohort study and interrupted time-series analysis","volume":"71","author":"Rezel-Potts","year":"2021","journal-title":"Br J Gen Pract"},{"key":"2024022909295953200_dlae013-B8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/23744235.2020.1839672","article-title":"Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in the Netherlands","volume":"53","author":"Karami","year":"2021","journal-title":"Infect Dis (Lond)"},{"key":"2024022909295953200_dlae013-B9","first-page":"2459","article-title":"Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing","volume":"71","author":"Rawson","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024022909295953200_dlae013-B10","doi-asserted-by":"crossref","first-page":"dlaa071","DOI":"10.1093\/jacamr\/dlaa071","article-title":"Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection","volume":"2","author":"Townsend","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"2024022909295953200_dlae013-B11","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1093\/cid\/ciaa1239","article-title":"Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multi-hospital cohort study","volume":"72","author":"Vaughn","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024022909295953200_dlae013-B12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3390\/antibiotics10060745","article-title":"Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: a scoping review","volume":"10","author":"Cong","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2024022909295953200_dlae013-B13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/14787210.2022.2011719","article-title":"Antimicrobial consumption in patients with COVID-19: a systematic review and meta-analysis","volume":"20","author":"Khan","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024022909295953200_dlae013-B14","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/trstmh\/trab048","article-title":"Key considerations on the potential impacts of the COVID-19 pandemic on antimicrobial resistance research and surveillance","volume":"115","author":"Rodr\u00edguez-Ba\u00f1o","year":"2021","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2024022909295953200_dlae013-B15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/jac\/dkaa194","article-title":"COVID-19 and the potential long-term impact on antimicrobial resistance","volume":"75","author":"Rawson","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024022909295953200_dlae013-B16","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-020-0395-y","article-title":"Antimicrobial use, drug-resistant infections and COVID-19","volume":"18","author":"Rawson","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"2024022909295953200_dlae013-B17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s13337-021-00695-2","article-title":"The potential impact of the COVID-19 pandemic on antimicrobial resistance and antibiotic stewardship","volume":"32","author":"Subramanya","year":"2021","journal-title":"VirusDisease"},{"key":"2024022909295953200_dlae013-B18","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1093\/jac\/dkaa350","article-title":"Implications of antibiotics use during the COVID-19 pandemic: present and future","volume":"75","author":"Miranda","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2024022909295953200_dlae013-B19","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1016\/S2666-5247(21)00090-2","article-title":"Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study","volume":"2","author":"Russell","year":"2021","journal-title":"Lancet Microbe"},{"key":"2024022909295953200_dlae013-B20","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/irv.12739","article-title":"Sixty-eight consecutive patients assessed for COVID-19 infection: experience from a UK regional infectious diseases unit","volume":"14","author":"Easom","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"2024022909295953200_dlae013-B21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jinf.2020.09.024","article-title":"Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals","volume":"81","author":"Seaton","year":"2020","journal-title":"J Infect"},{"key":"2024022909295953200_dlae013-B22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1757177420976813","article-title":"Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters?","volume":"22","author":"Evans","year":"2021","journal-title":"J Infect Prev"},{"key":"2024022909295953200_dlae013-B23","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3390\/antibiotics11111600","article-title":"COVID-19 mixed impact on hospital antimicrobial stewardship activities: a qualitative study in UK-based hospitals","volume":"11","author":"Khan","year":"2022","journal-title":"Antibiotics"},{"key":"2024022909295953200_dlae013-B24","volume-title":"Time Series Analysis: Forecasting and Control","author":"Box","year":"1976"},{"key":"2024022909295953200_dlae013-B25","author":"UKHSA"},{"key":"2024022909295953200_dlae013-B26","author":"WHO Collaborating Centre for Drug Statistics Methodology","year":"2022"},{"key":"2024022909295953200_dlae013-B27","author":"WHO Collaborating Centre for Drug Statistics Methodology"},{"key":"2024022909295953200_dlae013-B28","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S1473-3099(22)00683-1","article-title":"The WHO AWaRe antibiotic book: providing guidance on optimal use and informing policy","volume":"22","author":"Sharland","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024022909295953200_dlae013-B29","volume-title":"Time Series Analysis and Forecasting","author":"Liu","year":"2005"},{"key":"2024022909295953200_dlae013-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-6-16","article-title":"Using intervention time series analyses to assess the effects of imperfectly identifiable natural events: a general method and example","volume":"6","author":"Gilmour","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"2024022909295953200_dlae013-B31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/01621459.1975.10480264","article-title":"Intervention analysis with applications to economic and environmental problems","volume":"70","author":"Box","year":"1975","journal-title":"J Am Stat Assoc"},{"key":"2024022909295953200_dlae013-B32","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.3390\/ijerph19074005","article-title":"Antibiotic use in suspected and confirmed COVID-19 patients admitted to health facilities in Sierra Leone in 2020\u20132021: practice does not follow policy","volume":"19","author":"Kamara","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2024022909295953200_dlae013-B33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1017\/ice.2021.362","article-title":"The impact of coronavirus disease 2019 (COVID-19) on healthcare-associated infections in 2020: a summary of data reported to the national healthcare safety network","volume":"43","author":"Weiner-Lastinger","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024022909295953200_dlae013-B34","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1017\/ice.2021.237","article-title":"Impact of the strategies implemented by an antimicrobial stewardship program on the antibiotic consumption in the COVID-19 pandemic","volume":"43","author":"Murgadella-Sancho","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2024022909295953200_dlae013-B35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/antibiotics12010045","article-title":"Increasing consumption of antibiotics during the COVID-19 pandemic: implications for patient health and emerging anti-microbial resistance","volume":"12","author":"Malik","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2024022909295953200_dlae013-B36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jac\/dkad025","article-title":"Antimicrobial consumption and drug utilization patterns among COVID-19 and non-COVID-19 patients","volume":"78","author":"Antunes","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2024022909295953200_dlae013-B37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s43440-023-00479-z","article-title":"Hospital antibiotic consumption-an interrupted time series analysis of the early and late phases of the COVID-19 pandemic in Poland, a retrospective study","volume":"75","author":"Siewierska","year":"2023","journal-title":"Pharmacol Rep"},{"key":"2024022909295953200_dlae013-B38","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/antibiotics11060826","article-title":"Long-term impact of the COVID-19 pandemic on in-hospital antibiotic consumption and antibiotic resistance: a time series analysis (2015\u20132021)","volume":"11","author":"Meschiari","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2024022909295953200_dlae013-B39","doi-asserted-by":"crossref","first-page":"1067973","DOI":"10.3389\/fphar.2023.1067973","article-title":"Antibiotic consumption and antimicrobial resistance in the SARS-CoV-2 pandemic: a single-center experience","volume":"14","author":"Sokolovi\u0107","year":"2023","journal-title":"Front Pharmacol"},{"key":"2024022909295953200_dlae013-B40","author":"UKHSA"},{"key":"2024022909295953200_dlae013-B41","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1111\/bcp.15778","article-title":"The impact of the COVID-19 pandemic on antibiotic consumption and prevalence of pathogens in primary and secondary healthcare settings in Northern Ireland","volume":"89","author":"Aldeyab","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2024022909295953200_dlae013-B42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/antibiotics10020132","article-title":"Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic","volume":"10","author":"Grau","year":"2021","journal-title":"Antibiotics"},{"key":"2024022909295953200_dlae013-B43","author":"[NG173] Ng"},{"key":"2024022909295953200_dlae013-B44","doi-asserted-by":"crossref","first-page":"dlaa105","DOI":"10.1093\/jacamr\/dlaa105","article-title":"Impact of the COVID-19 pandemic on community antibiotic prescribing in Scotland","volume":"2","author":"Malcolm","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"2024022909295953200_dlae013-B45","author":"WHO"},{"key":"2024022909295953200_dlae013-B46","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cmi.2022.08.009","article-title":"The WHO essential medicines list AWaRe book: from a list to a quality improvement system","volume":"28","author":"Sharland","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024022909295953200_dlae013-B47","author":"WHO"},{"key":"2024022909295953200_dlae013-B48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4236\/pp.2022.1310029","article-title":"Antibiotic prescribing patterns in adult patients according to the WHO AWaRe classification: a multi-facility cross-sectional study in Primary Healthcare Hospitals in Lusaka, Zambia","volume":"13","author":"Mudenda","year":"2022","journal-title":"Pharmacol Pharm"},{"key":"2024022909295953200_dlae013-B49","author":"WHO"},{"key":"2024022909295953200_dlae013-B50","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/S2213-2600(21)00265-4","article-title":"Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave?","volume":"9","author":"Raut","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024022909295953200_dlae013-B51","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4269\/ajtmh.21-0608","article-title":"Rampant increase in cases of mucormycosis in India and Pakistan: a serious cause for concern during the ongoing COVID-19 pandemic","volume":"105","author":"Ghazi","year":"2021","journal-title":"Am J Trop Med Hyg"},{"key":"2024022909295953200_dlae013-B52","author":"WHO Solidarity Trial Consortium"},{"key":"2024022909295953200_dlae013-B53","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with COVID-19\u2014preliminary report","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"2024022909295953200_dlae013-B54","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/S0140-6736(23)00510-X","article-title":"Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"401","author":"Abani","year":"2023","journal-title":"Lancet"},{"key":"2024022909295953200_dlae013-B55","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2589-7500(22)00018-8","article-title":"Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO clinical characterisation protocol UK: prospective, cohort study","volume":"4","author":"N\u00e4rhi","year":"2022","journal-title":"Lancet Digit Health"},{"key":"2024022909295953200_dlae013-B56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.7326\/M22-3582","article-title":"Drug repurposing and observational studies: the case of antivirals for the treatment of COVID-19","volume":"176","author":"Hern\u00e1n","year":"2023","journal-title":"Ann Intern Med"},{"key":"2024022909295953200_dlae013-B57","doi-asserted-by":"crossref","first-page":"e216468","DOI":"10.1001\/jamanetworkopen.2021.6468","article-title":"Effect of early treatment with hydroxychloroquine or lopinavir and ritonavir on risk of hospitalization among patients with COVID-19: the TOGETHER randomized clinical trial","volume":"4","author":"Reis","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2024022909295953200_dlae013-B58","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1503\/cmaj.211698","article-title":"Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial","volume":"194","author":"Ali","year":"2022","journal-title":"CMAJ"},{"key":"2024022909295953200_dlae013-B59","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2024022909295953200_dlae013-B60","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2024022909295953200_dlae013-B61"},{"key":"2024022909295953200_dlae013-B62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","article-title":"Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection","volume":"29","author":"Hwang","year":"2022","journal-title":"J Biomed Sci"},{"key":"2024022909295953200_dlae013-B63","volume-title":"StatPearls","author":"Brobst","year":"2023"},{"key":"2024022909295953200_dlae013-B64","doi-asserted-by":"crossref","first-page":"100418","DOI":"10.1016\/j.eclinm.2020.100418","article-title":"Tocilizumab for treatment of patients with severe COVID\u201319: a retrospective cohort study","volume":"24","author":"Kewan","year":"2020","journal-title":"eClinicalMedicine"},{"key":"2024022909295953200_dlae013-B65","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1002\/jmv.25801","article-title":"Tocilizumab treatment in COVID-19: a single center experience","volume":"92","author":"Luo","year":"2020","journal-title":"J Med Virol"},{"key":"2024022909295953200_dlae013-B66","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1093\/cid\/ciaa954","article-title":"Tocilizumab for treatment of mechanically ventilated patients with COVID-19","volume":"73","author":"Somers","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2024022909295953200_dlae013-B67","doi-asserted-by":"crossref","first-page":"e069317","DOI":"10.1136\/bmj-2021-069317","article-title":"Public health impact of covid-19 vaccines in the US: observational study","volume":"377","author":"Suthar","year":"2022","journal-title":"BMJ"},{"key":"2024022909295953200_dlae013-B68","article-title":"Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK\u2019s COVID-19 infection survey","author":"Pritchard","year":"2021","journal-title":"medRxiv"},{"key":"2024022909295953200_dlae013-B69","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1017\/S0950268813001052","article-title":"Hospital antibiotic use and its relationship to age-adjusted comorbidity and alcohol-based hand rub consumption","volume":"142","author":"Aldeyab","year":"2014","journal-title":"Epidemiol Infect"},{"key":"2024022909295953200_dlae013-B70","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jac\/dkt458","article-title":"A modified method for measuring antibiotic use in healthcare settings: implications for antibiotic stewardship and benchmarking","volume":"69","author":"Aldeyab","year":"2014","journal-title":"J Antimicrob Chemother"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae013\/56756026\/dlae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/6\/1\/dlae013\/56756026\/dlae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T09:32:44Z","timestamp":1709199164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlae013\/7602540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,28]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlae013","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,12,28]]},"article-number":"dlae013"}}